Clinical Care

What your doctor can do that lifestyle can't: a few screening tests, a few prescriptions that genuinely change outcomes, and the blood markers that decide who benefits. Most of what is sold around them, from hormone "optimisation" to whole-body scans, does far less than its marketing.

Measure your blood pressure at home and treat it to an average below 130/80; add apoB to your yearly bloods and test lipoprotein(a) once; do the short list of cancer screens and stop there; and fix sleep, weight, alcohol and activity before asking for any hormone. Blood-pressure and cholesterol drugs and, for people with obesity and heart disease, semaglutide deliver effects behaviour alone cannot match, on large randomised trials; much of the hormone-optimisation, lab-panel and reference-range evidence is observational or guideline judgment, and each section says which.

Benefit tracks how far you have drifted

Response tends to be proportional to how far someone has drifted from a healthy baseline; adults "optimising" from a good start gain much less, sometimes nothing. One testosterone registry called this Wilder's Law of Initial Value. It is a way to read the evidence, not a finding: semaglutide's heart benefit is randomised but was only tested in people who already had heart disease,[1] the menopausal timing idea is observational, and the registry's own 77% mortality reduction is best explained by selection bias.[2]

Blood pressure: the best-proven lever, and a lifelong one

In the randomised SPRINT trial, 9,361 high-risk adults treated to an intensive systolic target had 25% fewer major cardiovascular events and 27% lower deaths from any cause.[3] Once pressures drifted back after the trial, the survival advantage was gone by a median 8.8 years, so blood pressure control is lifelong, not a course.[4]

The 2025 US guideline makes below 130/80 the target: medication for everyone at 140/90 or above, and between the two straight away only with heart, kidney or diabetic disease or a 10-year risk of 7.5% or more, otherwise after three to six months of lifestyle change fails.[5] Potassium-enriched salt substitutes are rated "reasonable", and not for people with kidney disease or on potassium-sparing drugs without potassium checks.[6]

Home readings run the diagnosis, because a clinic visit misses two patterns. Masked hypertension, normal in the clinic and high at home, is found in roughly 15–30% of adults whose office reading looks normal, and they go untreated.[7] Their risk of a cardiovascular event runs about 70% higher.[8] Untreated white-coat hypertension carries about a third more cardiovascular events,[9] and over 11 years about half of people with it developed sustained hypertension, against 18% of others.[10]

It probably protects thinking too. In SPRINT's memory study, the intensive target did not significantly reduce probable dementia, its main goal, but cut mild cognitive impairment by 19%;[11] at about seven years the effect persisted but was shrinking.[12]

Bedtime dosing failed in two large trials, of over 21,000 and over 3,300 people.[13][14] Isometric exercise lowered pressure most in a pooled analysis of 270 trials, about 8 mm Hg systolic, in the range of one drug (a loose comparison), but the wall-squat ranking rests on only four effect sizes.[15]

Cholesterol: count particles, and start early

Plaque builds with the lifetime dose of particles carrying apolipoprotein B (apoB), not with any one reading,[16] and genetic data suggest up to three times the benefit per unit of cholesterol lowered when lowering starts early.[17] In about one adult in five, apoB is out of line with LDL cholesterol, so a reassuring LDL can hide a high particle count.[18] That acting on apoB rather than LDL changes outcomes rests on observational data.

Non-statin drugs clear the same particles by other routes, with benefit tracking how far apoB falls: bempedoic acid cut major events by 13% in 13,970 statin-intolerant adults;[19] a PCSK9 antibody took median LDL from 92 to 30 mg/dL and cut events by 15–20%, depending on the endpoint.[20] So the theory that statins work through special non-cholesterol effects is largely settled.[21]

A coronary calcium scan breaks a tie. When a statin decision at borderline-to-intermediate risk is genuinely uncertain, it turns probability into anatomy. Zero buys only about 3–7 years, and not for smokers, people with diabetes or a strong family history.

Statin muscle aches are mostly not the statin, in the one trial that tested it. Sixty adults who had quit statins over side effects took statin, placebo and no-tablet months in random order: symptom scores averaged 8.0 with no tablet, 16.3 on the statin and 15.4 on placebo, so about 90% of the burden came with the placebo too.[22] One small trial in a selected group, but the right test before giving a statin up.

Test lipoprotein(a) once. It is a causal risk factor, more than 90% genetic, barely moved by diet or exercise and not lowered by statins; roughly 20% of adults carry enough to matter.[23] The 2026 US cholesterol guideline recommends one test for every adult, while treating apoB more narrowly, as reasonable mainly once LDL goals are met on treatment.[24] A high result means controlling everything else harder, not yet a treatment target: the first outcome trial of an Lp(a)-lowering drug, pelacarsen, missed its main goal in 2026.[25]

Labs: a short panel beats the annual physical

Randomised trials of general health checks made little or no difference to deaths from any cause or from cancer,[26] or to cardiovascular events.[27] A short midlife panel does change decisions: apoB, fasting insulin with HbA1c, hs-CRP, ferritin with transferrin saturation, uric acid and basic organ panels each year, plus Lp(a) once. Over 30 years in 27,939 women, the top fifth for hs-CRP had about 70% more cardiovascular events, a stronger signal than LDL cholesterol gave.[28]

Refusing tests matters as much. Skip NMR lipoprotein profiles when apoB is available,[29] IgG food panels, salivary "adrenal stress" panels,[30] routine IGF-1 in healthy adults, and provoked heavy-metal challenges.[31]

Cancer screening: a short list, and a real cost to the rest

A few cancer screens earn their place, on randomised and guideline evidence: mammography every two years from 40;[32] bowel screening from 45;[33] an HPV test every five years from 30 to 65 (every three if you take the sample yourself), which finds 40% more serious precancerous lesions per round than the smear test[34] and so justifies the longer gap;[35] a yearly low-dose lung CT at 50–80 after 20 or more pack-years, for people who still smoke or quit within 15 years;[36] and one-time checks for hepatitis C at 18–79[37] and, for men 65–75 who ever smoked, an aortic aneurysm. The American Cancer Society drops the lung 15-year cutoff.[38]

Pooling 18 trials in 2.1 million people, the average life gained from six common screens was days, not years.[39] Non-cancer deaths did not rise measurably with screening (0.2%, indistinguishable from zero).[40]

Overdiagnosis is the real cost. An estimated 72–94% of US papillary thyroid cancers diagnosed between 1991 and 2019 were overdiagnoses, driven by neck ultrasound.[41] Roughly 1 in 5 cases of ductal carcinoma in situ (DCIS) in a screened population is overdiagnosis.[42] Among 1,780 women whose DCIS was not operated on, 8.5–14% developed invasive cancer over eight years in an observational study,[43] against 36–39% over 30-plus years in older untreated series,[44] and a randomised trial found monitoring low-risk DCIS no worse than surgery at two years.[45] The 2025 American Thyroid Association guideline says active surveillance may be offered for selected small papillary cancers, a conditional recommendation on low-certainty evidence.[46]

PSA testing is a trade-off: over 23 years it cut prostate-cancer deaths by 13%, about 2 per 1,000 men invited; about 456 men invited and 12 diagnosed prevent one death (ranges 306–943 and 8–26).[47] Discuss it; don't order it by reflex.

Multi-cancer blood tests are not ready. The NHS-Galleri trial in over 142,000 people missed its primary endpoint; its results so far are a 2026 conference abstract and the maker's own account.[48] It found more early-stage cancers, but stage is a stand-in outcome, and finding slow cancers faster looks the same. The UK National Screening Committee wants randomised evidence on deaths first;[49] the US Task Force has no position.

GLP-1 drugs: a real heart benefit, a real muscle cost

Semaglutide is the first weight-loss drug with a hard cardiovascular outcome. In a randomised trial of about 17,600 non-diabetic adults with overweight or obesity and established heart disease, major cardiovascular events fell from 8.0% on placebo to 6.5% on semaglutide over about 40 months, roughly 20% fewer; the maker, Novo Nordisk, funded it.[50] See Ozempic-class drugs. Two-thirds of the lost weight returned within a year of stopping,[51] so like blood-pressure and cholesterol drugs, the benefit lasts only while you take it.

The anti-aging case is one small exploratory trial. In the semaglutide aging-clock trial, 32 weeks of the drug slowed several DNA-methylation clocks by roughly 1.4 to 4.9 epigenetic years per calendar year, in a post-hoc, exploratory analysis of 45 people on drug and 39 on placebo with HIV-related fat redistribution, profiled by the company that sells the clocks.[52] Omega-3 supplements had already slowed three clocks, more modestly, in a larger trial of older adults.[53] Using one clock reading to drive an individual decision is not established.[54]

Microdosing in healthy adults has no randomised evidence, and since the FDA declared the shortages over, much of what is sold as compounded or "research use only" is unapproved, with no check on dose accuracy, sterility or salt form.[55]

Muscle and bone are the price of the weight loss. A quarter to a third of the weight lost is fat-free mass, much as with intensive dieting.[56] Hip bone density fell about 2.6% over a year in a phase 2 trial of adults already at raised fracture risk,[57] a loss larger in non-diabetic weight loss than in type 2 diabetes.[58] Without enough protein and regular resistance training it leads toward sarcopenic obesity; a joint advisory proposes 1.2–1.6 g/kg a day, or 80–120 g, and warns against sustained intake at or above 2 g/kg.[59]

The other harms. Nausea affects about 44% against 16% on placebo, and 4.3% stop over gut effects.[60] Gallbladder disease rises about 37% overall and more than doubles in weight-loss trials.[61] Pancreatitis and a paralysed stomach are rare (about 4.6 and 9.1 cases per 1,000 person-years) but several times more common than on a comparison drug, on wide uncertainty.[62] Sudden painless vision loss in one eye, from a stroke of the optic nerve (NAION), has been linked to semaglutide in cohort studies;[63][64] the absolute risk is very low and later studies disagree on whether it is raised at all (see semaglutide and vision loss), but any new loss of vision needs same-day eye care, and the drug should be stopped if NAION is confirmed.

Testosterone: a treatment for deficiency, not a longevity drug

The heart fear is settled, and so is the diabetes hope. The randomised TRAVERSE trial gave 5,204 men with confirmed deficiency testosterone or placebo: heart attack, stroke or cardiovascular death struck 7.0% against 7.3%, no detectable difference.[65] A pre-specified substudy found no slowing of progression to type 2 diabetes, so testosterone should not be used to prevent or treat it.[66] In February 2025 the FDA dropped the cardiovascular warning, kept the statement that safety and efficacy in "age-related hypogonadism" are not established, and extended a blood-pressure warning to every product.[67]

Fix the reversible causes first, as the Endocrine Society advises: sleep, sleep apnoea, exercise, alcohol and weight;[68] the American Urological Association asks clinicians to counsel on lifestyle but does not require it first. About a quarter of men prescribed testosterone never had a level drawn beforehand.[69]

More is not better. A 2026 genetic study found men predisposed to higher lifelong testosterone had about 17% higher odds of coronary artery disease, largely through blood pressure, and no effect in women.[70] Lifelong exposure is not months of restoring a deficient man, but it argues against pushing a healthy man toward a 25-year-old's levels.

Cognition is a null in the two largest randomised trials, though TRAVERSE found modest gains in mood and energy;[71][72] a 2025 meta-analysis claiming moderate gains contradicts its own results and shows publication bias.[73]

The side effects to watch. TRAVERSE also recorded more atrial fibrillation, acute kidney injury, lung clots, raised blood pressure on ambulatory monitoring, and more fractures (3.5% against 2.5% over about three years).[74] It found no more prostate cancer, but it excluded men with a raised PSA, a prostate nodule or severe urinary symptoms, so PSA monitoring stays standard. Thickened blood (a haematocrit of 54% or above) is the most consistent side effect. It also halts sperm production; men who want children need a different approach. Compounded products bypass checks on dose and sterility, and the global consensus discourages compounded testosterone for women wherever an approved product is available.[75]

Menopausal hormone therapy: timing, route and progestogen decide it

Menopausal hormone therapy relieves hot flashes and protects bone, and the delivery details decide the risks. A patch or gel carries less clotting and stroke risk than estrogen pills.[76] In a large French cohort, breast cancer risk did not rise with micronised progesterone over shorter use and was 69% higher with other synthetic progestogens;[77] past about five years of use, even progesterone carried about 31% higher risk.[78] For vaginal dryness and painful sex, low-dose vaginal estrogen or vaginal prasterone are the best-established treatments, with minimal absorption into the body.[79]

Plan the stop. Current use lowers fracture odds by about 25%. In the one to ten years after stopping they return to never-user levels, slightly above after combined therapy (about 14 extra fractures per 10,000 woman-years, mostly after under five years' use), then fall below again; that window needs a taper or a bridging drug.[80]

It is not a heart drug. Started within ten years of menopause, estrogen goes with better heart outcomes in observational data; the two timing trials (ELITE supportive, KEEPS null) measured artery thickness and calcium and reduced no heart attacks, strokes or deaths. Pooling the randomised trials, hormone therapy had no effect on deaths overall, with about 30% fewer only in the trials that started it early.[81] The Women's Health Initiative's 20-year review concludes it should not be used to prevent chronic disease at any age.[82] Started early, it neither harms nor independently preserves cognition.[83]

Who should be careful. Starting in the late sixties or later raises heart attack, stroke and clot risk in the first year or two, a different proposition from continuing established therapy. Current or recent use carries a small ovarian-cancer excess, roughly one extra death per 1,700 women taking it for five years from about 50,[84] a reason to review it yearly, not to refuse it. For women who can't or won't take hormones, neurokinin blockers treat hot flashes; estetrol is a newer estrogen, not an alternative to one.

Thyroid: don't treat a number

A slightly high thyroid-stimulating hormone (TSH) in someone who feels well needs a repeat test, not a pill. In a randomised trial of 737 adults aged 65 and over with TSH 4.6–19.99, levothyroxine improved nothing: not symptoms, energy, thinking, grip strength or artery thickness; heart events were no less common, though the trial was too small and short to test them.[85] About 58% of mildly raised readings went back to normal on their own within a median three years, and TSH runs higher in winter and spring.[86] See Thyroid management.

The normal range is being rewritten. Age- and demographic-specific limits reclassify 48.5% of "subclinical hypothyroidism" as normal;[87] a workable shortcut in older adults is an upper limit of age divided by 10, so 7.0 at seventy.[88] Long-lived people run higher TSH, an argument against pushing a well person's TSH down but not for suppressing the thyroid: mice held mildly hypothyroid lived a normal lifespan with severe insulin resistance, fatty liver and aggressive liver cancer.[89] For symptoms that persist on levothyroxine, adding T3 helps a little on average.

Iodine sufficiency may matter, on thin data. Over 20 years, an iodine-rich Danish town had about 40% lower adjusted mortality than an iodine-poor one, but only 428 people were followed to the end, so the size is indicative, not precise.[90] Iodised salt and seafood at 150 µg a day do the work; kelp and Lugol's megadosing do the opposite.

Topics covered in depth

Midlife labs →

What to draw yearly, once, or only for a symptom, and the marketed tests to refuse.

Blood pressure management →

The target, the home protocol, single-pill combinations and the wall squat.

Lipid management →

apoB and lifetime exposure, the calcium scan, statins through PCSK9 inhibitors, and lipoprotein(a).

Cancer screening cadence →

Which tests, not how many: the high-value list, overdiagnosis, and an honest read on multi-cancer blood tests.

Ozempic-class drugs →

Semaglutide and tirzepatide: weight loss, the heart outcome, and the muscle, bone and tolerability costs.

Testosterone therapy →

What TRAVERSE settled, what the genetics complicate, why the mortality registry fails, and how to diagnose and monitor.

Menopausal hormone therapy →

Timing, route and progestogen as three decisions; bone, brain and cancer; non-hormonal options.

Thyroid management →

Why a slightly high TSH is usually nothing, symptoms on levothyroxine, and the ultrasound-driven cancer epidemic.

Practical guidance

  1. Correct the reversible inputs first. Poor sleep, untreated sleep apnoea, alcohol, stress, endocrine-disrupting chemicals and overtraining suppress your own testosterone; obesity, inactivity and ultra-processed food drive what GLP-1 drugs treat.
  2. Get the baseline labs. Yearly: apoB, fasting insulin, HbA1c (a three-month average of blood sugar; with fasting insulin it gives a simple insulin-resistance index), hs-CRP, ferritin with transferrin saturation, uric acid, a blood count and a metabolic panel. Once: lipoprotein(a). Only for symptoms: TSH, two morning testosterone draws, estradiol and follicle-stimulating hormone.
  3. Measure blood pressure at home. Seven days (three at the shortest), twice a day, two readings 1–2 minutes apart, seated and silent; if you discard day one, add a day at the end. Act on the home average.
  4. On the fence about a statin, get one calcium scan. Zero buys a few years (rescan in 3–7) unless you smoke, have diabetes or a strong family history.
  5. Aim for the middle of the range, not the top. The lifelong-testosterone genetics are the strongest argument, reinforced by the U-shaped mortality curves this site documents for uric acid and insulin-like growth factor 1 (IGF-1). Repletion, not optimisation.
  6. Pair every prescription with lifestyle, and monitor it. Resistance training and protein with a GLP-1 drug; sleep-apnoea screening and haematocrit checks with testosterone; a plan for the fracture window when stopping hormone therapy.
  7. Know the red flags. A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 rules out GLP-1 drugs; prior severe pancreatitis or an active eating disorder are strong reasons not to start; stop at least two months before a planned pregnancy. Anyone with a history of hormone-sensitive cancer needs specialist input before sex-hormone therapy.

What's overrated

  • Testosterone as a longevity drug. It treats documented, symptomatic deficiency; no randomised trial has shown it extends life.
  • GLP-1 drugs for Alzheimer's disease. Two phase 3 trials in 3,808 people missed their main goal;[91] a favourable spinal-fluid shift comes from a company presentation, not the peer-reviewed report.
  • Whole-body MRI and CT for healthy adults. No randomised evidence on deaths, plenty of false alarms. Routine skin checks in average-risk adults are similar: a review of 20 studies in over 6 million people found no population-level fall in melanoma deaths.[92]
  • Smartwatch blood-pressure readings as a diagnosis. A trend tool at best; the US guideline says not to rely on them and the European one doesn't recommend them for routine use.
  • Chasing "subclinical" findings. A mildly high TSH, a borderline ferritin, one high hs-CRP in a stressful week.

What this category is not

  • Not medical advice. These are evidence summaries; decisions about a specific patient belong to a specific clinician.
  • Not "preventive optimisation". Lifestyle comes first; this pillar exists because some interventions only happen through a clinician.
  • Not marketing. Household names (Ozempic-class drugs) are for plain language, not endorsement.

For the full ordered action list drawn from every pillar, see the healthspan long list.

— § —